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ABSTRACT
Background
Older individuals are at high risk for musculoskeletal impairment following hospitalization due
to decreased neuromuscular function and bone mineral density (BMD) arising from illness itself,
and external factors such as immobilization and changes in nutritional status. To address the
knowledge gap regarding the longitudinal impact of COVID-19 on musculoskeletal outcomes,
this thesis aimed to study the relationship between COVID-19 severity and physical functional,
incidence of falls and fractures in older adults. Secondarily, in a subset of patients we examined
the relationship between COVID-19 severity and osteoporosis- and sarcopenia-related measures.
Methods
This study analyzed data from the VALIANT study and VALIANT MSK Sub-study. The
VALIANT study included individuals who were over 60 years old and were hospitalized due to
COVID-19 in the Yale New Haven Hospital System (YNHHS) from July 2020-July 2021.
Virtual interviews were performed at the time of hospitalization, and 1, 3, and 6-months posthospitalization and measured a range of sociodemographic, clinical and general health-related
characteristics, physical function domains relevant to musculoskeletal health and mobility, and
incident falls and fractures. Patients who consented to be re-contacted were invited to participate
in the VALIANT MSK Sub-study and presented for an in-patient visit which included a survey,
serum sample collection, a dual-energy x-ray absorptiometry test, the short physical performance
battery and grip strength assessment. Descriptive statistics were used to evaluate primary and
secondary outcomes, stratified by COVID-19 severity as defined by SOFA score, inpatient level

of care, and inflammatory markers (high-sensitivity C-reactive protein and interleukin-6) at
baseline and 6 months.
Results
Among 341 participants enrolled in the VALIANT parent study, the median age was 70.0 years
(IQR 12) , with 49% female, and 72.5% White individuals while among the 62 participants in the
VALIANT MSK Sub-Study, the median age was 67.0 years (IQR 10), with 49% females, and
64.2% White individuals. In the VALIANT cohort, when physical function status at 6 months
was stratified by COVID-19 severity, multiple domains emerged as being significantly different.
A higher proportion of patients who had a higher SOFA score (≥3) reported being unable to
independently bathe (9.2% vs 2.4%, p<0.001), get in and out of a chair (5.8% vs 1.7%, p=0.017),
use the toilet (3.8% vs 0.3%, p=0.006), shop (20.1% vs 11.6%, p=0.011), or walk flight of stairs
(15.4% vs 8.2%, p=0.016). A significantly higher proportion of VALIANT participants with
high inpatient hsCRP levels during hospitalization (≥97 mg/L) were unable to independently do
housework (31.7% vs 21.1%, p= 0.013), shop (33.1% vs 19.7%, p=0.043), walk a quarter mile
(28.5% vs 24.2%, p=0.009) and walk flights of stairs (37.0% vs 15.9%. p= 0.0114). In the
VALIANT MSK Sub-study, a similar general trend was observed with a higher proportion of
patients with SOFA scores ≥3 or hsCRP≥97 mg/L reporting that they were unable to
independently perform certain physical function tasks.
At baseline, 101/339 (29.8%) VALIANT participants reported a fall in the past year
before COVID-19 compared with 15/62 (24.2%) of VALIANT MSK Sub-Study participants. At
6 months, 24.3% of VALIANT participants reported having an incident fall since COVID
infection compared with 19.4% of VALIANT MSK participants. When participants of both
groups were categorized based on COVID severity no significant differences were seen in the

proportion of new falls in the 6 months. Seven participants overall reported having a fracture
following COVID-19 hospitalization.
Among the VALIANT MSK participants, 3 participants (5.2%) had osteoporosis and 22
participants (37.9%) had osteopenia. Mean femoral neck (FN) BMD was lower among patients
with hsCRP ≥97 (0.79 vs 0.21, p<0.001). Five participants (8.1%) met criteria for probable
sarcopenia. No participants met criteria for sarcopenia or severe sarcopenia. When examining
individual sarcopenia assessment components, there was no statistically significant difference
when categorized based on COVID severity.
Conclusions
Our study shows that a greater proportion of older adults presenting with severe COVID-19 as
defined by SOFA, inpatient level of care, or high hsCRP and high IL-6 had worse physical
functional status and lower FN BMD at six months. Further multivariable analyses should
explore whether these associations remain when adjusted for key musculoskeletal health-related
covariates, and how baseline status is associated with outcomes at 6 months. Attention to the
rehabilitation needs of patients following COVID-19 hospitalization is important, as well as
consideration for osteoporosis and sarcopenia screening for those with more severe disease.
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INTRODUCTION
Older individuals are at high risk for fracture in the months following hospitalization due
to decreased neuromuscular function and bone mineral density (BMD) arising from illness,
immobilization, and changes in nutritional status.1 This risk may be compounded among patients
hospitalized with severe or critical coronavirus disease 2019 (COVID-19), which is characterized
by hyperinflammation.2 Concurrently, from the macroscopic perspective of functional recovery,
inpatient and post-discharge rehabilitation services are relatively restricted for patients with
COVID-19, and access to caregivers at home and healthcare providers may be limited. All these
factors create a perfect storm for prolonged disability, and increased falls and fractures among
older patients hospitalized with COVID-19.
Osteoporosis is characterized by low bone mass and microarchitectural deterioration of
bone tissue.3 Osteoporosis is a risk factor for fracture and is the most common metabolic bone
disorder.4 It is a major public health issue as there are typically no symptoms in the early stages
of bone loss; with the first visible sign of the disease being a fracture. 4Bone tissue is constantly
lost by resorption and rebuilt by formation.4 Bone loss occurs when the rate of resorption is
higher than rate of formation.3 As people age the creation of new bone tissue cannot keep up
with the loss of old bone tissue; bone mass is lost faster than it is created.3Around 10 million
individuals over age 50 in the US has osteoporosis of the hip and 33.6 million individuals over
age 50 are at risk of osteoporosis with low bone density known as osteopenia.5As the U.S.
population ages, the prevalence of osteoporosis and low bone mass is expected to increase. 5

Sarcopenia is also a major cause of functional decline and mortality in older adults.6
Decline of functional ability with age is a direct results of muscle weakness, loss of muscle force
due to decline skeletal muscle mass.6 In older adults aged 65-70, the prevalence of sarcopenia
may be as high as 24%.6 Older adults with sarcopenia on admission are 5 times more likely to
have higher hospital costs than older adults without sarcopenia.7 Sarcopenia increases risk of
falls and fractures and is also associated with a wide range of comorbidities including cardiac
disease, respiratory disease, and cognitive impairment, all of which leads to mobility disorder
and loss of independence contributing towards lower quality of life.8
There has been a growing interest in common pathways of sarcopenia and osteoporosis
such as hormonal pathways, immune inflammatory pathways and cross talk between skeletal
muscles and bone cells through molecule interactions. In osteoimmunology studies, it has been
suggested that systemic inflammation is linked to bone loss through proinflammatory cytokines
such as interleukin 6 which can stimulate bone resorption10 Interleukin 6 is also suggested to play
a crucial role in the hyperinflammatory state characterized in patients with severe COVID-19.11
To address this gap in knowledge of COVID on musculoskeletal outcomes, this thesis aimed to
study the relationship between COVID severity and musculoskeletal health by functional status
and incidence of falls and fractures in a cohort of patients over 60 years of age who were
admitted to the Yale New Haven Hospital System (YNNHS) with COVID-19, and also identify
sociodemographic, clinical and COVID-19-related risk factors that may impact this relationship.
We hypothesized that more severe COVID-19 infection will be associated with worse
musculoskeletal outcomes including greater likelihood of decline in functional status, and higher
incidence of falls and fractures at 6 months.

METHODS
Study Design and Ethics Approvals
We performed a prospective longitudinal study of older adults hospitalized with COVID-19 at
Yale New Haven Health System (YNHHS). This thesis utilized two data sets: the VALIANT
(COVID-19 in Older Adults: A Longitudinal Assessment) study and VALIANT MSK (COVID19 in Older Adults: A Longitudinal Assessment Musculoskeletal outcomes) sub-study. The
research protocol for the parent study and sub-study were reviewed and approved by Yale
University Institutional Review Board (IRES IRB). Due to the COVID-19 pandemic, a safety
work plan was also submitted and approved by Yale University Environmental Health & Safety
through the Human Research Study office. Verbal consent (VALIANT) and written consent
(Sub-study) were obtained from patients prior to any interviews or in-person visit procedures
were conducted.

Sample
VALIANT study
Recruited patients for the VALIANT study (HIC #2000028175) included individuals who are
over 60 years old and were hospitalized due to COVID-19 and admitted into the YNHHS from
July 2020-July 2021. Details of the parent study and baseline participant characteristics have
recently been submitted for publication. In brief, patients were contacted by research personnel
via YNHHS Insight video monitors. Patients completed a baseline interview, 1-month, 3-month
and 6-month interviews. Interviews were conducted remotely (by phone or by video) and
participants answered questions regarding their sociodemographic characteristics, baseline

health, COVID-related factors, and measures related to functional status and healthcare received
since hospitalization for COVID-19.
Inclusion criteria: age >= 60 years old, hospitalized or recently hospitalized with COVID at
YNHHS, have not opted out of research
Exclusion criteria: unable to provide informed consent and no proxy available, requested
research opt-out, planned discharge to hospice/advance directive of “comfort measures only”,
long term residents of extended-care facilities, deceased, advanced dementia
VALIANT MSK sub-study
A subgroup of participants from VALIANT were invited to participate in a follow up study
focused on musculoskeletal outcomes (HIC #2000030426) at 6-9 months post-infection. Patients
were recruited from July 2020 to July 2021. Willing participants had an in-person hospital visit
at 6-9months post-infection. This in-person study visit included a blood draw, a brief selfadministered risk factor survey, DXA scan (bone mineral density and body composition
assessments) and physical assessments (SPPB and grip strength).
Inclusion criteria: completed VALIANT study 6-month interview, agree to be contacted for
related studies, primary residence in Connecticut
Exclusion criteria: opt out of being contacted for related studies, unable to physically come to the
study site or perform study activities (e.g., wheelchair bound)

Measures

The primary study aim was to evaluate the association between baseline severity of COVID-19
with musculoskeletal outcomes at 6 months, including physical function (including decline from
baseline), functional expectations at 6 months, and incident falls and fracture in patients enrolled
in the VALIANT study. In a subset of participants enrolled in the VALIANT MSK sub-study,
we explored the association of baseline severity of COVID-19 with secondary exploratory
outcomes including bone mineral density (BMD)/osteoporosis and sarcopenia at 6-9 months
post-hospitalization.
Exposures
Data regarding exposures was collected through a survey administered by study staff, and
through medical chart review. COVID severity during hospitalization was evaluated using three
approaches: highest level of care (floors vs. stepdown unit/intensive care unit), Sequential Organ
Failure Assessment score (SOFA scores, <3 vs. ≥3) evaluating the six major organ function, and
levels of inflammatory markers including high sensitivity C-reactive protein (65.5 vs. 97) and
IL-6 (37 vs. 80) if available.
Data was also collected regarding baseline sociodemographic characteristics (age, sex, race,
place/type of residence), baseline clinical characteristics (body mass index, smoking/alcohol use
status, comorbidities and medications, general baseline health status, hearing/vision impairment),
COVID-19 related factors (duration of hospitalization, treatments for COVID-19, rehabilitation
services during and after hospitalization, other home care services required after hospitalization).
Primary Outcomes
Primary outcomes were measured as part of the VALIANT parent study. Physical function was
measured via 9 survey items regarding disability in activities of daily living associated with

mobility/musculoskeletal function (Ability to bathe, get in and out of chair, use the toilet, do
housework, shop, walk in your house, walk a quarter mile, require a device to walk a quarter
mile and ability walking flight of stairs. Answer choices are No need help, Need help and unable
to) Use of assistive devices are also considered (cane, walker, wheelchair and other device. Selfreported falls and fracture history at baseline, and new falls and fractures since COVID-19
hospitalization at 6 months was used to determine incidence of each.
Secondary Outcomes
Secondary measures were measured during VALIANT MSK Substudy activities, including a
brief survey regarding fracture risk factors (sociodemographic, smoking and alcohol history and
history of falls), SARC-F score8 and dietary calcium intake assessment.
All participants also underwent a comprehensive DXA scan performed by trained DXA
technicians at the Yale Bone Center. DXA includes bone and body composition scans yielding
bone mineral density and regional body composition. Dual X-ray absorptiometry (DXA) is the
preferred diagnostic tool to measure bone mineral density (BMD) measurements of the femoral
neck, total hip and lumbar spine.3 These measurements are used in the diagnosis of osteoporosis
and prediction of fracture risk.3 For this study, we will measure the bone mineral density (g/cm2)
as well as the T-score, which is generated by comparing the BMD of the individual to the mean
BMD of a young healthy standard reference population.3 This score is used to classify patients as
having normal BMD, osteopenia or osteoporosis.3
Sarcopenia is often under-diagnosed and undertreated due to the complexity of measuring
muscle mass and muscle quality. 8 The proposed study utilizes the sarcopenia definition updated
in 2019 by the European Working Group on Sarcopenia in Older People (EWGSOP).8 This

definition combines the SARC-F screening tool, and Short Physical Performance Battery (SPPB)
to assess for and determine severity of sarcopenia. SARC-F is a simple and rapid questionnaire
consists of 5 questions on strength, assistance in walking, rise from a chair, climb stairs, and
falls. SPPB is a short physical assessment consist of a balance test, a 4-meter gait speed test, and
a chair stand test.9 For this study, we further used DXA total body lean tissue mass
measurements as a confirmation of muscle quantity and quality. 8
Lastly, we performed the SPPB physical assessment and upper extremity handgrip test using a
Jamar hydraulic hand dynamometer. These tests are well-established measurements for lower
and upper extremity physical function assessment that are feasible in clinical care settings and
are associated with short-term mortality, disability, hospitalization among other outcomes.8
Fasting blood samples were also collected from each study participant and stored for future
analyses of bone turnover and bone metabolism biomarkers.

Data Analysis
All analyses were performed using SAS (SAS 9.4 TS1M7 MBCD3170), and followed best
practices for analyzing and accounting for limitations of observational data.
At the outset of data analysis, all variables were examined linearly using descriptive techniques.
Stratified analyses of the primary and secondary outcomes were carried out for patients based
upon the exposure groups (SOFA score, hospital ward, and inflammatory markers) dichotomized
as described above. T-tests were applied for continuous variables, Wilcoxon rank sum tests for
ordered/non-normally distributed variables, and chi-squared tests for non-ordered categorical
variables. All statistical tests were two-tailed with a significance level set at alpha (α) < 0.05.

Key baseline covariates related to the outcomes of interest (e.g., known/suspected risk factors for
bone fracture based on the literature such as age, sex, tobacco use, medications associated with
bone loss, duration of immobilization/hospitalization) will be examined in univariate analyses
and those that reach a significance level of p<0.2 will be considered for inclusion in future
multivariable models.
RESULTS
Baseline characteristics of study participants
Sociodemographic Characteristics
A total of 341 participants were enrolled in the VALIANT parent study, and of those, 62
participants subsequently participated in the VALIANT MSK Sub-Study. Baseline
characteristics of study participants are shown in Table 1.
The median age of participants in VALIANT was older than that of participants in VALIANT
MSK [(70 vs. 67 years (p<0.001)]. Other characteristics were statistically similar between the
two groups. Women comprised 49% of the participants in both groups. Most patients in both the
parent study and sub-Study were White with 219 participants (72.5%) in VALIANT and 34
participants (64.2%) VALIANT MSK. Black participants comprised 26.5% of the overall
VALIANT cohort, and 34% of those who enrolled in VALIANT MSK. Less than 2% of
participants in both groups were Asian.
Participants’ living situation at baseline was similar between those in the overall VALIANT
sample and those who participated in the Sub-study. The majority of patients lived at home with
others at baseline (70.5% and 64.5%, respectively), approximately one-third lived at home alone,
and fewer participants reported living in a short-term rehabilitation or assisted living facility at

baseline. None of the patients enrolled in the VALIANT MSK Sub-study lived in an assisted
living facility at baseline.
Health-Related Characteristics
Approximately three quarters of patients in both groups rated their general health as good, very
good, or excellent prior to being hospitalized with COVID-19. More individuals enrolled in the
VALIANT study reported never smoking compared with those in the VALIANT MSK SubStudy [146 (47.6%) vs. 19 (35.2%) participants, p=0.096]. Alcohol use data was only available
for sub-study participants, and on 2 (3.5%) participants reported consuming more than 3 units of
alcohol per day.
The median BMI was at 30.0 (IQR 9.1) kg/m2 for participants in VALIANT and 30.5 (IQR 9.1)
among those who enrolled in the sub-study. Participants in VALIANT had a median comorbidity
count of 3 (IQR 3) those in VALIANT MSK has a median comorbidity count of 2 (IQR 2).
Those enrolled in the sub-study had lower rates of chronic kidney disease, end stage renal
disease, cardiovascular disease, heart failure, and cancer, and higher rates of myocardial
infarction, immunocompromised status (history of autoimmune disease, HIV, or solid organ
transplant) and liver disease. However, these differences were not statistically different. In both
groups, over 75% of patients had hypertension and approximately 45% of participants suffered
from diabetes.
Factors Related to COVID-19 Hospitalization
Participants in the MSK Sub-Study had a similar median duration of COVID hospitalization [7
(IQR 6) days] compared to those in the overall VALIANT study [8 (IQR 6) days]. Data were
available for four medications or medication classes related to each participant’s COVID-19

hospitalization, including dexamethasone, remdesivir, tocilizumab. Participants in the VALIANT
MSK sub-study participants were more likely to receive remdesivir compared to those who were
not enrolled in the sub-study (87% v. 68.9%, p=0.0037). Rates of treatment with dexamethasone
(74.2% vs 62.7%) and Tocilizumab (27.4% vs 18.3%) were also higher among patients enrolled
in the sub-study, although these did not reach statistical significance.

COVID-19 Severity
Table 1 shows the measures related to COVID-19 severity. The median inpatient SOFA score
was 3 for both groups. In terms of required level of care, the majority of the participants were
admitted into the general hospital floors [272 participants (80.0%) in VALIANT and 46
participants (74.2%) in VALIANT MSK]. There were 29 participants (8.5%) in VALANT who
received care in the SDU compared to 10 participants (16.1%) in the sub-study. Similar
proportions of participants required intensive care [40 participants (11.7%) in VALIANT and 6
(10.0%) in VALIANT MSK, p=0.057]. When looking at inpatient markers of inflammation, the
median IL-6 level was 20.6 pg/ml for participants in VALIANT and 48.9 pg/ml for those in the
VALIANT MSK Sub-study (p=0.4353), whereas median hsCRP levels were 90.1mg/L and
118.8 mg/L for participants in the parent study versus sub-study, respectively (p=0.6581).

Musculoskeletal Outcomes
Physical Function

Baseline physical function status differed in certain domains between the overall cohort of
VALIANT participants and those enrolled in the MSK sub-study (Table 2). Specifically, in the
overall cohort, a higher proportion of participants reported being unable to independently use the
toilet (5.6% vs 0.0%, p=0.034, do housework (30.4% vs 13.0%, p=0.004), shop (28% vs 10.0%,
p=0.0014) and walk up a flight of stairs (24.3% vs 10.0%, p=0.011).
Overall baseline physical function status and 6 months physical function status are relatively
similar. There were 38.0% of participants at 6 months who are unable to independently walk a
quarter mile as compared to 32.5% of participants at baseline. On the other hand, there were
4.1% participants who are unable to independently use the toilet as compared to 5.6% of
participants at baseline. Similar trends were observed in the VALIANT MSK sub-study. Overall
baseline physical function status and 6 months physical function status are similar.
In the VALIANT cohort, when physical function status at 6 months was stratified by COVID-19
severity, multiple domains emerged as being significantly different. A higher proportion of
patients who had a higher SOFA score (≥3) reported being unable to independently bathe (9.2%
vs 2.4%, p<0.001), get in and out of a chair (5.8% vs 1.7%, p=0.017), use the toilet (3.8% vs
0.3%, p=0.006), shop (20.1% vs 11.6%, p=0.011), or walk flight of stairs (15.4% vs 8.2%,
p=0.016). No significant differences were observed in physical function domains based upon
inpatient level of care received. A significantly higher proportion of VALIANT participants with
high inpatient hsCRP levels during hospitalization (≥97 mg/L) were unable to independently do
housework (31.7% vs 21.1%, p= 0.013), shop (33.1% vs 19.7%, p=0.043), walk a quarter mile
(28.5% vs 24.2%, p=0.009) and walk flights of stairs (37.0% vs 15.9%. p= 0.0114). When
stratified analyses were performed based upon inpatient IL-6 levels, the proportion of patients

who noted difficulty with physical function was higher across several domains among those with
higher IL-6 levels (≥37), however none of these differences were statistically significant.
Among patients enrolled in the VALIANT MSK Sub-study, a similar general trend was observed
with a higher proportion of patients with SOFA scores ≥3 or hsCRP≥97 mg/L reporting that they
were unable to independently perform certain physical function tasks, however none of these
were statistically significant and, in several domains, it was not possible to performed stratified
analyses due to the low total number of patients reporting difficulty in that domain.
Use of Assistive Devices
At baseline, the 16.5% of participants in VALIANT reported using a cane, 17.7% used a walker,
and 5.6% used a wheelchair. A similar proportion of participants reported using canes (15.7%)
and walkers (18.0%) at 6 months, however the proportion of patients using wheelchairs
increased to 8.2% although this was not statistically significant.
In the overall cohort of patients in VALIANT, patients with a SOFA score ≥3 were more likely
to report use of a walker (12.6% v. 5.4%, p=0.006) and wheelchair (6.1% vs. 2.0%, p=0.023) at 6
months compared with those with a SOFA score <3. When stratified by inpatient level of care,
those who received step down or ICU-level care were less likely to report using a cane at 6
months (0.68% vs. 15%, p=0.017). When stratifying based upon inpatient inflammatory marker
levels, a higher proportion of VALIANT participants who had low hsCRP level reported using a
cane at 6 months (10.5 vs 5.3, p=0.045) and there was a general trend of higher use of assistive
devices among participants with inpatient Il6 levels <37 ng/mL, including use of canes (12.6%
vs 4.9%) and walkers (15.5% vs 5.8%). However, these differences were not statistically
significant.

Among participants who enrolled in the VALIANT MSK Sub-Study, the proportion of patients
using a cane remained unchanged from baseline to six months (16.1%), however use of other
assistive devices (walker, wheelchair, or other device) increased slightly, although this change
did not reach statistical significance. When stratified by COVID-19 severity, no significant
differences were seen based upon SOFA Score category. Among patients who were treated in
the SDU/ICU, there was a lower proportion of participants using a cane at 6 months (12.9% vs
3.2%, p=0.65). Finally, a higher proportion of patients with hsCRP <97 mg/L and IL-6 level <37
pg/mL reported using a cane compared to patients with higher inpatient inflammatory marker
levels. Participants with Il-6 levels <37 pg/mL also reported high rates of using a walker (11.1%
vs 6.7%) or a wheelchair (4.4% vs 0.0%), although as with the overall VALIANT cohort, these
differences were not statistically different.
Falls and Fractures
At baseline, 101/339 (29.8%) VALIANT participants reported a fall in the past year before
COVID-19 compared with 15/62 (24.2%) of VALIANT MSK Sub-Study participants. At 6
months, 24.3% of VALIANT participants reported having an incident fall since COVID
infection compared with 19.4% of VALIANT MSK participants.
When participants were categorized based on SOFA scores no significant differences were seen
in the proportion of new falls in the 6 months after COVID-19 hospitalization among the
VALIANT participants (11.3% vs 13.1%) or VALIANT MSK participants (8.1% vs 11.3%). A
higher proportion of participants who received care on the general medical floors reported a fall
as compared to the SDU/ICU in both VALIANT (21.0% vs 3.4%, p-value=0.60) and VALIANT
MSK Sub-Study participants (14.5% vs 4.9%, p-value=0.94). Similarly, when categorized by
inpatient hsCRP or Il-6 levels, a higher proportion of participants reported falling since COVID-

19 hospitalization in the low hsCRP group (14.1% vs 10.6% in VALIANT and 11.9% vs 8.5% in
VALIANT MSK) and low Il-6 group (18.6 vs 6.4% in VALIANT and 15.6% vs 2.2% in
VALIANT MSK). However, these differences did not reach statistical significance.
No data were collected regarding fracture history at baseline, however 7 participants (2.4%)
reported a fracture after hospitalization for COVID-19 in the VALIANT cohort, compared with 1
participant (1.6%) within the VALIANT MSK sub-study (p=0.55). The number of fractures
reported was not sufficient to detect statistically significant differences between COVID-19
severity groups.
Osteoporosis and Fracture Risk
Table 3 demonstrates osteoporosis and Sarcopenia-Related Outcomes at 6 Months in the
VALIANT MSK Substudy, Overall and by Severity Categories (N=62). Out of the 62
VALIANT MSK participants, 3 participants (5.2%) had osteoporosis, 22 participants (37.9%)
had osteopenia and 37 participants (63.8%) had normal BMD. When stratified by SOFA score,
level or care, or inpatient inflammatory marker levels, no significant differences were seen
between the two groups. However, among these, a greater proportion of participants with Il-6
levels ≥37 pg/mL met criteria for osteopenia compared with those with Il-6 values <37 (40.0%
vs 30.0%).
The mean of lumbar spine (LS) BMD among participants in the MSK Sub-Study was 1.15±0.23
g/cm2, mean total hip (TH) BMD was 0.98±0.21 g/cm2, and mean femoral neck (FN) BMD was
0.82±0.19 g/cm2. Mean LS BMD and TH BMD levels remained relatively similar when stratified
by SOFA score, level of care and inflammatory marker levels. However, mean FN BMD was
lower among patients with hsCRP ≥97 (0.79 vs 0.21, p<0.001).

The mean of FRAX score for 10-year risk of major osteoporotic fracture was 6.94±5.1 and mean
FRAX score for10-year risk of hip fracture was 1.31±1.8. No significant differences were
observed between patients when stratified by inpatient SOFA scores, level of care or
inflammatory marker levels.
Sarcopenia
Among patients in the VALIANT MSK Sub-Study, five participants (8.1%) met criteria for
probable sarcopenia. No participants met criteria for sarcopenia or severe sarcopenia. Four of the
participants with probable sarcopenia had a SOFA score of 3.
When examining individual sarcopenia assessment components, 21(33.9%) participants had a
SARC-F score >4, and 13(21.0%) had altered grip strength, 27(43.5%) had altered SPPB and
4(6.5%) had altered ASMI. Among participants with SARC-F scores >4, statistical differences
were not seen by COVID-19 severity category.
Among patients with altered grip strength, no significant differences were seen by COVID-19
severity category. A higher proportion of altered grip strength participants in floor level care
(10/47, 27.9% vs 3/16, 18.8%). There is a relatively similar proportion of altered grip strength
participants in both hsCRP level groups and il6 level groups.
There is a higher proportion of altered SPPB participants in the SOFA 3 and above group (17/37,
45.9% vs 10/25, 38.5%). There is also a higher proportion of altered SPPB participants in the
floor level of care group (20/46, 55.6% vs 7/17, 43.8%). hsCRP and il6 levels has relatively
similar proportion of altered SPPB participants within each groups. There is relatively similar
proportion of altered ASMI participants within the SOFA score, level of care, hsCRP and il6
categories.

DISCUSSION
To our knowledge this is the first study to longitudinally evaluate musculoskeletal
outcomes after COVID-19 hospitalization among older adults, and to study the impact of
severity of COVID-19 on these outcomes. In the VALIANT cohort, when physical function
status at six months was stratified by COVID-19 severity, multiple domains emerged as being
significantly different. We observed a higher proportion of patients who had a higher SOFA
score reported being unable to independently bathe, get in and out of a chair, use the toilet, shop
and walk up a flight of stairs. There was also a significantly higher proportion of participants
with high hsCRP levels during their hospitalization who were unable to independently do
housework, shop, walk a quarter mile and walk up a flight of stairs at six months. Interestingly,
when stratified analyses were performed based on inpatient level of care received, no significant
differences were observed. Although differences did not reach statistical significance, among
those with high IL-6 levels, there was a general trend of higher proportions of patients with
physical function limitations across several domains.
Much of COVID-19 literature has focused on the biology, and acute clinical
manifestations and outcomes of the virus, and intermediate-term aftereffects such as long covid
(or post-acute sequelae of COVID-19), defined by symptoms persisting four to twelve weeks
post infection.12 Moreover, COVID-19 also disproportionally affects older adults. Huang and
colleagues, carried out a large cohort study in Wuhan, China describing 6-month health
consequences of 2469 hospitalized adult patients with COVID-19 based on disease severity.13
However, their study was more focused on severe cases of COVID, pulmonary function and
treatment-related aftermath of COVID-19 hospitalized patients and less on general long-term
consequences. Furthermore, there was no mention of bone and muscle health. The present study

focuses uniquely on 6-month health consequences of patients over the age of 60 years
hospitalized for COVID-19, and also looks specifically at their bone and muscle health outcomes
in relation COVID-19 severity.
According to the NIH COVID treatment guidelines, COVID severity is classified into
asymptomatic, mild, moderate, severe, and critical based on clinical assessment or imaging of
oxygen saturation. There have also been presented studies at 2021 FDA Science Forum
conducted recently by Center for Drug Evaluation and Research that have looked at respiratory
support as a measurement for COVID severity (supplemental oxygen, non-invasive ventilation,
or invasive mechanical ventilation). Although these are all valid measurements, they focus on
one major organ system – the respiratory system and do not consider other potential important
complications, which may be particularly important in older adults, our population of interest.
We therefore chose to define severity using three different perspective, including a clinical
measure of multi-organ function, the SOFA score, level of care received as a reflection of overall
intensity of medical and nursing services required during hospitalization, and levels of serum
inflammatory markers, hsCRP and IL-6 which may reflect the degree of hyperinflammation due
to COVID-19.
SOFA scores have been used in the intensive care unit to predict clinical outcomes of
patients with multiple organ failure. 14 It has been suggested that SOFA scores could be used to
evaluate COVID-19 severity and potentially mortality risk, and have been linked to lower
physical function in this population. This measure is based on the evaluation of 6 major organ
functions: circulation, respiration, hepatic, renal, central nervous system and coagulation
functions, and each organ is given a score between 0-4. 14 It is considered an easy-to-use
systematic tool during hospitalization yet there have also been studies that suggest that due to use

of mechanical ventilation on critical ill patients with COVID pneumonia SOFA score is not a
good presentation of patient status. 14 The findings from our study are consistent in that greater
proportions of patients with higher SOFA scores were found to have limitations in multiple
physical function domains relevant to musculoskeletal health, and to report use of walkers or
wheelchairs at six months.
Contrary to what we expected, care on the general medical floors was related to more
reported falls in the six months following hospitalization as compared to patients the SDU/ICU
in both the VALIANT and VALIANT MSK Sub-study participants. Inpatient level of care (Floor
vs SDU/ICU) reflects both medical treatment and nursing related factors including the ratio of
nurses to patients and hence would provide valuable insight into overall hospital stay but also
severity of COVID symptoms. It is possible more falls were observed in patients who received
care on the general medical floors due to earlier and more unsupervised attempts at mobility, or
less attention to physical therapy or home care needs post-discharge.
We observed a general trend of patients having physical function difficulty across several
physical function domains in the group of patients with high hsCRP or high IL-6 levels, although
the differences for IL-6 did not reach statistical significance. HsCRP is a commonly used
biomarker for general inflammation 15 and has been shown in the literature to be positively
correlated with myocardial injury in critical cases of COVID.15 Interleukin 6 (IL-6) is suggested
to contribute toward the proinflammatory cytokine storm in more severe COVID-cases and has
also been associated with poor outcomes in COVID-19. 16 Particularly relevant for our study,
systemic inflammation is known to be linked to bone loss due to increased activation of
osteoclasts, which are responsible for bone resorption. 16

One of the major findings in this study is that mean FN BMD was shown to be lower
among patients with hsCRP ≥97 mg/L. To date, osteoporosis risk in the setting of COVID-19 has
mostly been analyzed from the lens of bone loss from immobility due to COVID-19
containment. 17 Although osteoporosis is considered a treatable and preventable condition, it is
suggested that alterations in mobility and physical activity leads to acute changes in body
composition described as osteosarcopenic obesity which promotes oxidative stress and
proinflammatory cytokines 17. It has been suggested that there is considerable musculoskeletal
dysfunction in some patients with COVID-19, however, few studies have actually measured
bone and muscle health after COVID-19 infection. This is the first COVID cohort study
specifically looking at musculoskeletal outcomes after 6 months hospitalization. At the
beginning of the COVID pandemic, multiple papers described clinical manifestation of SARS
2003 in order to raise awareness regarding potential manifestations that may be seen with
COVID-19. 18 They suggested certain musculoskeletal consequences and mechanisms which
may aid our understanding of the current COVID-19 infection. 18 For example, skeletal muscle,
synovium, and cortical bone are potential sites of direct SARS-CoV-2 infection. 18This may
potentially compound the other potential sociodemographic and clinical risks for bone and
muscle impairment in our population of interest, such as older age, history of falls and general
health.
The present study did not find statistically significant differences in rates of sarcopeniarelated measures in our study, although this may be related to the modest size of our sample.
There have been limited studies on sarcopenia and COVID-19, with only one review that we are
aware of focused on acute sarcopenia and its impact on muscle degradation in COVID-19,
especially for older adults. Acute sarcopenia refers to the acute loss of muscle mass and function

associated with hospitalization. We utilized the definition developed by European Working
Group on Sarcopenia in Older people (EWGSOP2) and performed physical assessment with
VALIANT MSK participants based on this definition. It is suggested that the combination of
multiple environmental factors such as decreased nutrition, increased physical inactivity and
acute hospitalization may intensify acute sarcopenia for patients with COVID-19. 19 Some prior
studies have focused on the relationship between acute sarcopenia and hospitalization, but have
not previously studied COVID-19 related hospitalization. Similar to our hypothesis, these studies
have found patients’ underlying comorbidities, inflammation, nutritional status and physical
function status to be factors associated with sarcopenia outcomes.
Contrary to what we expected, a higher proportion of participants who received care on
the general medical floors reported a fall as compared to the SDU/ICU in both VALIANT and
VALIANT MSK Sub-study participants. However, these differences did not reach statistical
significance. Furthermore there were not enough fracture events in our cohort to draw
conclusions regarding the relationship between COVID-19 hospitalization, COVID-19 severity,
and fractures. Future larger studies are needed explore both falls and fracture outcomes further.
This study had several limitations. This cohort study was limited to a single health system
in the U.S. and therefore results cannot be generalized to a wider population. The sample size
was relatively small, especially when observing clinical outcomes such as falls or fractures. As
this is an observational study, this study is more susceptible to selection bias and confounding.
Importantly, the next steps for analysis will use multivariable regression to evaluate the
relationship between COVID-19 severity and musculoskeletal outcomes adjusted for key
covariates (e.g., age, BMI, smoking history, and other bone-health related factors) . In addition,
we acknowledge that an added limitation to both the VALIANT and VALIANT MSK study was

the logistical barriers to participating in research during the COVID-19 pandemic, which meant
that patients with the most severe disease or greatest amount of disability may not have been able
to or willing to participate. Finally, as COVID-19 is relatively new and research is constantly
expanding in this field, the inflammatory marker cut offs we selected based on the currently
available literature is extrapolated from studies that were not focused specifically on
musculoskeletal outcomes. Therefore, future analyses will also seek to evaluate the most
appropriate thresholds for identifying patients at increased risk for poor musculoskeletal
outcomes. We hope that this study has shared some insights on COVID-19 severity and
musculoskeletal outcomes. Future studies should aim to further confirm and elucidate our
findings in larger cohorts, and help identify potential areas for prevention and intervention in
order to optimize the musculoskeletal health of older persons after COVID-19 infection.
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